A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome)

Pasquale Striano, Vito Sofia, Giuseppe Capovilla, Guido Rubboli, Carlo Di Bonaventura, Antonietta Coppola, Giuseppina Vitale, Luis Fontanillas, Anna Teresa Giallonardo, Roberto Biondi, Antonino Romeo, Maurizio Viri, Federico Zara, Salvatore Striano

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Eyelid myoclonia with absences (EMA) or Jeavons syndrome characterized by eyelid myoclonia (EM) (with or without absences), eye closure-induced EEG paroxysms, and photosensitivity. We conducted an open-label trial of levetiracetam in EMA. Patients and Methods: Patients were recruited in different Italian Epilepsy Centres. Levetiracetam was administrated at starting dose of 10 mg/kg/day up to 50-60 mg/kg/day in two doses. Treatment period included a 5-6 week up-titration phase and a 12-week evaluation phase. The number of days with EM (i.e., days with seizures, DwS) and number of generalized tonic-clonic seizures (GTCS) were evaluated. Analysis of intent-to-treat population was performed using Fisher's and Wilcoxon tests. Results: Thirty-five patients (23 F) with a mean age of 19 ± 6 years were recruited. Twenty-seven had previously undergone one to five adequate trials of antiepileptic drugs. The median number of DwS/month was 12 ± 8.2. Twenty-one patients experienced GTCS (median number/month: 1 ± 0.2). Thirty-four subjects completed the trial. Levetiracetam was well tolerated (mean dose: 1985 mg/day). Responders were 28/35 (80%) patients, nine taking levetiracetam as monotherapy. Six patients were seizure-free, 15 had ≥75% and seven >50% seizure reduction. GTCS remitted in 14 out of 21 (66.6%) patients. The number/month of DwS (median: 12 vs 5; p = 0.0001) and of GTCS (median: 1 vs 0; p = 0.0001) decreased compared to baseline period. Disappearance or clear reduction in paroxysmal abnormalities at eye closure occurred in 20 of the responders and photoparoxysmal response in 19. Mean follow-up was 23.9 ± 18.5 months. Conclusion: Levetiracetam is effective and well tolerated in EMA. Placebo-controlled studies should confirm these findings.

Original languageEnglish
Pages (from-to)425-430
Number of pages6
JournalEpilepsia
Volume49
Issue number3
DOIs
Publication statusPublished - Mar 2008

Keywords

  • AEDs
  • EMA
  • Epilepsy
  • Jeavons syndrome
  • Levetiracetam

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome)'. Together they form a unique fingerprint.

Cite this